A dual-modification strategy for P2-type layered oxide via bulk Mg/Ti co-substitution and MgO surface coating for sodium ion batteries.

P2-type materials are regarded as competitive cathodes for next generation sodium ion batteries. However, the unfavorable P2 â†’ O2 phase transition usually leads to severe capacity decay. Moreover, the cathode material always suffers from destruction of surface crystal structure caused by trace amount of HF. In this study, a dual-modification method containing Mg/Ti co-doping and MgO surface coating is designed to solve the defects of P2-type Na0.67Ni0.17Co0.17Mn0.66O2 cathode. Results turn out that the P2 structure can be stabilized via Mg/Ti co-substitution and MgO layer could effectively prevent the surface from corroding by HF and promote migration of Na+. Moreover, the as-prepared MgO-coated Na0.67Ni0.17Co0.17Mn0.66Mg0.1O2 exhibits improved electrochemical performance than the raw material. It delivers 111.6 mAh g-1 initial discharge capacity and maintains 90.6% at high current density of 100 mA g-1 within 2-4.5 V, which has been obviously enhanced than that of Na0.67Ni0.17Co0.17Mn0.66O2. The significant improvement can be attributed to the synergistic effect of Mg/Ti co-substitution and MgO surface coating. This dual-modification strategy based on the synergetic effect of Mg/Ti co-doping and MgO surface coating might be a resultful step forward to develop cathode materials for sodium ion batteries.

Comparison of TaqMan, KASP and rhAmp SNP genotyping platforms in hexaploid wheat.

Advances in high-throughput genotyping enable the generation of genome-scale data much more easily and at lower cost than ever before. However, small-scale and cost-effective high-throughput single-nucleotide polymorphism (SNP) genotyping technologies are still under development. In this study, we compared the performances of TaqMan, KASP and rhAmp SNP genotyping platforms in terms of their assay design flexibility, assay design success rate, allele call rate and quality, ease of experiment run and cost per sample. Fifty SNP markers linked to genes governing various agronomic traits of wheat were chosen to design SNP assays. Design success rates were 39/50, 49/50, and 49/50 for TaqMan, KASP, and rhAmp, respectively, and 30 SNP assays were manufactured for genotyping comparisons across the three platforms. rhAmp showed 97% of samples amplified while TaqMan and KASP showed 93% and 93.5% of amplifications, respectively. Allele call quality of rhAmp was 97%, while it was 98% for both TaqMan and KASP. rhAmp and KASP showed significantly better (p < 0.001) allele discrimination than TaqMan; however, TaqMan showed the most compact cluster. Based on the current market, rhAmp was the least expensive technology followed by KASP. In conclusion, rhAmp provides a reliable and cost-effective option for targeted genotyping and marker-assisted selection in crop genetic improvement.

Coffee Consumption and Pancreatic Cancer Risk: An Update Meta-analysis of Cohort Studies.

BACKGROUND & OBJECTIVE: The results of epidemiologic studies on the relationship between the coffee consumption and pancreatic cancer risk were inconsistent. Thus, we performed an update meta-analysis of cohort studies to quantitatively summarize the association between coffee consumption and pancreatic cancer risk. METHODS: We searched CBM (China Biology Medicine disc) and MEDLINE for studies of coffee consumption and pancreatic cancer risk up to June 2015. A total of 20 cohort studies were identified in this meta-analysis, and we analyzed these studies using random effects model. The dose-response analysis was conducted too. RESULTS: The overall relative risk (RR) for highest coffee consumption versus lowest coffee consumption was 0.75 (95% Confidence Interval (CI), 0.63-0.86). Statistic significant heterogeneity was found among these studies (I (2) =37.8%, P for heterogeneity =0.045). The pooled RR for increment of 1 cup/day of coffee consumption was 0.99 (95%CI, 0.96-1.03) for the nine studies, without statistically significant. CONCLUSIONS: High coffee consumption is associated with a reduced pancreatic cancer risk. However, the result should be accepted with caution, due to the potential confounder and bias could not be excluded. Further well designed studies are needed to confirm the finding.